1. Introduction {#sec1}
===============

The postoperative complications of colorectal cancer surgery result in increased ventilation days, hospital stay days, mortality, and cost. Postoperative infection is a major factor affecting the morbidity of the patients. Bacterial translocation is defined as transmitting the bacteria from the gastrointestinal tract to normally sterile tissues. A large number of studies have shown that the bacterial translocation plays a significant role in increasing the incidence of postoperative infections \[[@B1], [@B2]\].

The probiotics therapy, which was introduced by Lilly and Stillwell \[[@B3]\], could lead to positive clinical and laboratorial outcomes for patients undergoing gastrointestinal surgery. Probiotics are live microorganisms and it is known that probiotics benefit to the host as they can stabilize the intestinal microbiological environment. Nowadays, probiotics have been proved to treat several diseases, such as chronic inflammatory bowel disease \[[@B4]\], hepatic encephalopathy \[[@B5]\], and atopic disease \[[@B6]\]. Horvat et al. \[[@B7]\] showed us his interesting finding that preoperative administration of prebiotics in elective colorectal surgery had the same protective effect in preventing a postoperative inflammatory response as mechanical bowel cleaning.

Probiotics study is very important in recent year, there is a recent paper discussing about the importance of probiotics in the prevention and treatment of colorectal cancer. So we want to conduct a meta-analysis to integrate all this interesting studies to guide clinical practice, as meta-analysis has the higher quality than common RCTs if we only include high quality RCTs. We try to explore the incidence of post-operative infections, including the incidence of the total infection and subgroup infection, such as surgical site infection, central line infection, pneumonia, urinary tract infection, septicemia and postoperative leakage.

2. Methods {#sec2}
==========

2.1. Search Strategy {#sec2.1}
--------------------

Two investigators independently searched the articles in the databases (PubMed, the Web of Science). The reference lists of eligible studies and relevant papers were also manually searched and reviewed. Searching terms included "probiotics", "colorectal cancer", and "surgery". Searching terminal date was 2019/1/10. Firstly, we found 407 articles after duplications excluded, and then 307 of them were excluded by reading the title and abstract. Finally, 6 articles were left after reading the whole articles \[[@B8]--[@B13]\] ([Figure 1](#fig1){ref-type="fig"}).

2.2. Inclusion and Exclusion {#sec2.2}
----------------------------

Inclusions contain: (1) randomized controlled study comparing probiotics with placebo, (2) outcome: various kinds of infections, (3) only be published in English.

Exclusions contain: (1) review, retrospective research, case report, (2) insufficient data in the articles.

2.3. Data Elected {#sec2.3}
-----------------

Two authors (Chongxiang Chen, Tianmeng Wen) independently reviewed the identified abstracts and selected articles to full review. The third reviewer addressed the discrepancies (Qingyu Zhao). For each selected publication, the following baseline and study characteristics were extracted: first author, publication year, country, participant characteristics, patient age, dosage form of probiotics groups, experimental durations, and the baseline characteristics of these studies were concluded ([Table 1](#tab1){ref-type="table"}). The risk of bias of the included studies is shown in Figures [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}. Efficacy outcome measures were the total infection, surgical site infection, central line infection, pneumonia, urinary tract infection, septicemia, and postoperative leakage.

2.4. Risk of Bias Assessment {#sec2.4}
----------------------------

The risk of bias of trials included in this meta-analysis was assessed according to the recommendations of the Cochrane Handbook of Systematic Reviews of Interventions, in the following domains: selection bias (random sequence generation and allocation concealment), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessment), attrition bias (incomplete outcome data), and reporting bias (selective outcome reporting) (<http://handbook.cochrane.org>). Jadad scale was used to calculate the quality of every enrolled study.

2.5. Statistic Analysis {#sec2.5}
-----------------------

We pooled data and used mean deviation (OR, with 95% confidence interval) for dichotomy outcomes: the total infection, surgical site infection, central line infection, pneumonia, urinary tract infection, septicemia, and postoperative leakage. We would use a fixed-effect model if there were no considerable heterogeneity among the studies. We would use a random-effects model if the *I*^2^ statistic was above 50% and Cochran\'s Q statistic had a *P* value ≤0.1. Funnel plots were used to screen for potential publication bias. All statistical analyses were carried out with Review Manager 5.3 (The Cochrane Collaboration).

3. Results {#sec3}
==========

The studies included in our meta-analysis were all randomized controlled trials, published from 2010 to 2015. The studies were conducted in Greece \[[@B11]\], China \[[@B8], [@B9], [@B12], [@B13]\], and Japan \[[@B10]\]. [Table 1](#tab1){ref-type="table"} presents the basic characteristics of included trials and demographic data of participants. All trials were one-center studies and the Jadad Scales of all included studies ranged from 3 to 7.

3.1. Total Infection {#sec3.1}
--------------------

Comparing probiotics with placebo, our study showed that probiotics could significantly decrease the incidence of postoperative infections. For the total postoperative infection, our study included 3 studies with a total of 220 patients; the results by comparing groups were significantly lower in probiotics group (odd ratios (OR) 0.31, 95% confidence interval (CI) 0.15--0.64). Heterogeneity testing showed that *I*^2^ = 0%, indicating low heterogeneity ([Figure 4](#fig4){ref-type="fig"}).

3.2. Surgical Site Infection {#sec3.2}
----------------------------

For the incidence of surgical site infection, our study included 6 studies involving a total of 653 patients, and the result demonstrated that probiotics was significantly lower than placebo (OR 0.62, 95%CI 0.39--0.99, *I*^2^ = 11%). Heterogeneity testing showed that *I*^2^ = 11%, indicating low heterogeneity. ([Figure 5](#fig5){ref-type="fig"}).

3.3. Central Line Infection {#sec3.3}
---------------------------

For the results of the incidence of central line infection, our study enrolled 2 studies, including a total of 284 patients, central line infection (OR 0.61, 95%CI 0.15--2.45, *I*^2^ = 65%) reflected no significant difference in two groups. Heterogeneity testing showed that *I*^2^ = 65%, indicating high heterogeneity ([Figure 6](#fig6){ref-type="fig"}).

3.4. Pneumonia {#sec3.4}
--------------

For the incidence of pneumonia, our study enrolled 4 studies, including a total of 508 patients, and the result showed that probiotics was significantly lower than the placebo (OR 0.36, 95%CI 0.18--0.71, *I*^2^ = 0%). Heterogeneity testing showed that *I*^2^ = 0%, indicating low heterogeneity ([Figure 7](#fig7){ref-type="fig"}).

3.5. Urinary Tract Infection {#sec3.5}
----------------------------

For the result of the incidence of urinary tract infection, our study included 3 studies and a total of 448 patients, and the result reflected significant difference in groups (OR 0.26, 95%CI 0.11--0.60, *I*^2^ = 26%). Heterogeneity testing showed that *I*^2^ = 26%, indicating low heterogeneity ([Figure 8](#fig8){ref-type="fig"}).

3.6. Septicemia {#sec3.6}
---------------

For the result of the incidence of septicemia, our study enrolled 4 studies, including a total of 509 patients, and the result showed that probiotics was significantly lower than the placebo (OR 0.28, 95%CI 0.17--0.47, *I*^2^ = 10%). Heterogeneity testing showed that *I*^2^ = 10%, indicating low heterogeneity ([Figure 9](#fig9){ref-type="fig"}).

3.7. Postoperative Leakage {#sec3.7}
--------------------------

For the result of the incidence of postoperative leakage, our study enrolled 3 studies, including a total of 419 patients, and the result did not show that probiotics was significantly lower than the placebo (OR 0.45, 95%CI 0.06--3.27, *I*^2^ = 68%). Heterogeneity testing showed that *I*^2^ = 68%, indicating high heterogeneity ([Figure 10](#fig10){ref-type="fig"}).

Potential publication bias of probiotics used for surgical site infection was performed and shown as funnel plot ([Figure 11](#fig11){ref-type="fig"}).

4. Discussion {#sec4}
=============

Several RCTs showed that the use of probiotics in patients with abdominal surgery was a promising approach to the prevention of postoperative infectious complications and well tolerated by patients with minor side effects \[[@B14]\]. However, in abdominal surgery, some investigators reported that there was no evidence supporting any benefit of a preoperative use of probiotics in patients with critical illnesses and undergoing elective abdominal surgery with increased risk of mortality \[[@B15], [@B16]\], and that in some cases, there was even an increased risk of mortality.

In our meta-analyses, the results showed that probiotics could effectively decrease the rate of postoperative infections, such as pneumonia, surgical site infection, and urinary tract infection.

Not only the incidence of infections but also the quality of life is improved in these studies, which shortens the duration of postoperative hospital stay and the antibiotics administration period. Furthermore, probiotics are considered to generate antitumor agents, which have chemo-preventive effects against colorectal cancer \[[@B17]\]. In addition, probiotics can improve immune function \[[@B18]\].

It is shown that probiotics protect epithelial barrier function. The outcomes probably result from the balance of the enteral bacteria environment. The use of probiotics after surgery markedly improved intestinal microbial populations and significantly decreased the incidence of further infectious complications. The mechanism of the action of probiotics may be related with either the earlier bowel movement preventing bacterial translocation from the gut or the modulation of the innate immune responses.

Gastrointestinal microbiota may be modulated by probiotics. Our study demonstrated that the use of probiotics improved the capacity of the gut ecosystem to survive from surgically induced injury, resulting in fewer postoperative infections. Thus, we concluded that maintaining gut microbiota balance and diversity is important for enhancing host defenses, especially during the recovery from major surgery.

The drawbacks of our study are described as follows: Firstly, we only searched the studies written by English, and the total subjects included in our study were less than the study conducted by Ouyang et al. \[[@B19]\]. Moreover, the combination with prebiotics was not taken into account. Furthermore, the probiotics strain, dose and dosage form in collected studies were not consistent, and the probiotics treatment was combined with other pretreatment modes in some studies, which probably induced certain confusing factors.

However, our study calculated the results of the exactly total subgroups of infection, including the pneumonia, septicemia, central line infection, surgical site infection, postoperative leakage, and urinary tract infection. So our study contains more comprehensive viewpoints of the benefit of probiotics used in colorectal cancer patients undergoing surgery.

5. Conclusion {#sec5}
=============

All in all, probiotics is beneficial to prevent postoperative infections (including total postoperative infection, surgical site infection, pneumonia, urinary tract infection, and septicemia) in patients with colorectal cancer. We recommend perioperative oral intake of probiotics as the treatment in patients needing gastrointestinal surgery.

We acknowledge contribution of all authors.

Data Availability
=================

The datasets used and/or analyzed in the current study are available from the corresponding author upon request.

Consent
=======

All authors have agreed to the publication of this manuscript.

Conflicts of Interest
=====================

The authors declare that they have no coflicts of interest.

Authors\' Contributions
=======================

Chongxiang Chen designed the study. Chongxiang Chen, Qingyu Zhao designed the search strategy and performed the search. Chongxiang Chen, and Tianmeng Wen performed abstract screening, full text screening, data extraction, and risk of bias assessment. Chongxiang Chen and Qingyu Zhao drafted the manuscript. All authors revised the manuscript, as well as reading and approving the final manuscript.

![Flow diagram of choosing the appropriated articles.](BMRI2020-5734718.001){#fig1}

![Risk of bias summary.](BMRI2020-5734718.002){#fig2}

![Risk of bias graph.](BMRI2020-5734718.003){#fig3}

![Incidence of total infection.](BMRI2020-5734718.004){#fig4}

![Incidence of postoperative surgical site infection.](BMRI2020-5734718.005){#fig5}

![Incidence of postoperative central line infection.](BMRI2020-5734718.006){#fig6}

![Incidence of postoperative pneumonia.](BMRI2020-5734718.007){#fig7}

![Incidence of postoperative urinary tract infection.](BMRI2020-5734718.008){#fig8}

![Incidence of postoperative septicemia.](BMRI2020-5734718.009){#fig9}

![Incidence of postoperative leakage.](BMRI2020-5734718.010){#fig10}

![Funnel plot of surgical site infection.](BMRI2020-5734718.011){#fig11}

###### 

Baseline characteristics of these studies.

  Study                Type   Jadad scale (randomization + concealment of allocation+double blinding + withdrawals and dropouts)   Time (published)   Country          Participant   Total number (probiotics vs. placebo)   Age (probiotics vs. placebo)                           Probiotics                                                                                                                                                                                                     Duration
  -------------------- ------ ---------------------------------------------------------------------------------------------------- ------------------ ---------------- ------------- --------------------------------------- ------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------
  Kotzampassi et al.   RCT    1 + 1 + 2 + 1 = 5                                                                                    2015               Greece           One center    164; 84/80                              Total: ≥18 years; 65.9 ± 11.5 vs. 66.4 ± 11.9          One capsule (*Lactobacillus acidophilus* LA 5, *Lactobacillus plantarum*, *Bifidobacterium lactis* BB 12 *Saccharomyces boulardii*) twice a day                                                                The day of operation and for the next 14 days
  Liu et al.           RCT    2 + 1 + 2 + 1 = 6                                                                                    2012               China (Taiwan)   One RCC       150; 75/75                              Total: 25--75 years; 66.06 ± 11.02 vs. 62.28 ± 12.41   Encapsulated bacteria (*Lactobacillus plantarum*; *Lactobacillus acidophilus*11; *Bifidobacterium longum* 88) patients in probiotics group received 2 g/d, at a total daily dose of 2.6 × 10^14^ CFU           6 days preoperatively and 10 days postoperatively
  Liu et al.           RCT    2 + 2 + 2 + 1 = 7                                                                                    2015               China            One ICU       134; 66/68                              Total: 25--75 years; 66.62 ± 18.18 vs. 60.16 ± 16.20   Encapsulated probiotics (*Lactobacillus plantarum*; *Lactobacillus acidophilus*11; *Bifidobacterium longum* 88); patients in probiotics group received 2 g/d, at a total daily dose of 2.6 × 10^14^ CFU        Intervention period lasted 16 days, 6 days preoperatively and 10 days postoperatively; Detailed records were recorded for up to 30 days after surgery
  Sadahiro et al.      RCT    1 + 1 + 0 + 1 = 3                                                                                    2013               Japan            One ICU       195; 100/95                             Total: 20-80 years; 67 ± 9 vs. 66 ± 12                 Three Bifidobacteria tablets orally after each meal three times daily                                                                                                                                          For 7 days before the operation and from postoperative day 5 for 10 days
  Zhang et al.         RCT    1 + 1 + 2 + 1 = 5                                                                                    2011               China            One center    60; 30/30                               Total: None 61.5 (46--82) vs. 67.5 (45--87)            3 oral bifid triple viable capsules (*Enterococcus faecalis*; *Lactobacillus acidophilus*; *Bifidobacterium longum*), 3 times a day                                                                            For 3 days (days −5 to −3) before surgery
  Liu et al.           RCT    2 + 2 + 2 + 1 = 7                                                                                    2010               China            One center    100; 50/50                              Total: 25--75 years; 65.3 ± 11 vs. 65.7 ± 9.9          Encapsulated bacteria (contain: *Lactobacillus plantarum*; *Lactobacillus acidophilus*; *Bifidobacterium longum*); patients in placebo group received probiotics 2 g/d, total daily dose of 2.6 × 10^14^ CFU   6 days preoperatively and 10 days postoperatively

RCT: randomized controlled trial; ICU: intensive care unit; RCC: respiratory care center.
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